Nsp-Interleukin-10 Fusion Proteins for Treating Chronic Inflammatory Diseases

University of Pittsburgh researchers have developed a novel therapeutic approach using Nsp-Interleukin-10 (Nsp_IL10) fusion proteins to treat chronic inflammatory diseases such as osteoarthritis (OA). The delivery of this engineered molecule at the early stages of OA aims to reduce inflammation and pain, and delay tissue degeneration, offering a potential breakthrough in managing this prevalent degenerative joint disease.

The predicted protein structure of Nsp-IL10 from RaptorX, indicating no change in conformation of IL-10 in the fusion protein.

Description

The Nsp-Interleukin-10 (Nsp_IL10) fusion protein is a genetically engineered molecule combining a small linear peptide sequence of Nerve Growth Factor (NGF) with the immunomodulatory molecule interleukin-10. This dual-function protein is produced using viral expression systems and is designed to target and modulate key signaling pathways involved in inflammation and tissue degeneration. The therapeutic approach involves encapsulating the Nsp_IL10 protein or protein-producing vectors within biodegradable hydrogel scaffolds for localized, sustained release at the affected tissue site. This method aims to maintain joint function and reduce disease progression in OA and potentially other chronic inflammatory diseases.

Applications

• Treatment of osteoarthritis
• Management of chronic inflammatory diseases
• Immune modulation therapies

Advantages

This technology offers a novel approach to treating chronic inflammatory diseases by simultaneously targeting NGF/NGFR and interleukin-10 signaling pathways. The Nsp_IL10 fusion protein provides localized, sustained release, reducing inflammation and pain while maintaining tissue homeostasis. This approach has the potential to delay disease progression and improve the quality of life for patients with OA and other inflammatory conditions. The use of biodegradable hydrogel scaffolds ensures a durable and controlled delivery of the therapeutic protein.

Invention Readiness

The invention is currently supported by in vitro data demonstrating the efficacy of the Nsp_IL10 fusion protein in maintaining tissue homeostasis and reducing inflammation. Further development includes optimizing the protein's function and delivery method, and testing its therapeutic effect in biologically and clinically relevant animal models. Successful completion of these steps will pave the way for clinical applications and potential commercialization.

IP Status

https://patents.google.com/patent/US20210332098A1